Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 40

1.

Decreased expression of thrombomodulin is correlated with tumor cell invasiveness and poor prognosis in nonsmall cell lung cancer.

Liu PL, Tsai JR, Chiu CC, Hwang JJ, Chou SH, Wang CK, Wu SJ, Chen YL, Chen WC, Chen YH, Chong IW.

Mol Carcinog. 2010 Oct;49(10):874-81. doi: 10.1002/mc.20663.

PMID:
20607726
2.

The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets.

Krishnakumar R, Kraus WL.

Mol Cell. 2010 Jul 9;39(1):8-24. doi: 10.1016/j.molcel.2010.06.017. Review.

3.

Epidemiology and pathophysiology of cancer-associated thrombosis.

Noble S, Pasi J.

Br J Cancer. 2010 Apr 13;102 Suppl 1:S2-9. doi: 10.1038/sj.bjc.6605599. Review.

4.

Mesothelioma and internal carotid artery occlusion: acute ischemic stroke and efficacy of emergency carotid thrombectomy.

Ferrero E, Ferri M, Viazzo A, Gaggiano A, Berardi G, Piazza S, Cumbo P, Nessi F.

Ann Vasc Surg. 2010 Feb;24(2):257.e9-12. doi: 10.1016/j.avsg.2009.11.001. Epub 2009 Dec 29.

PMID:
20036493
5.

Malignant mesothelioma: biology, diagnosis and therapeutic approaches.

Tomasetti M, Amati M, Santarelli L, Alleva R, Neuzil J.

Curr Mol Pharmacol. 2009 Jun;2(2):190-206. Review.

PMID:
20021458
6.

Parp1 localizes within the Dnmt1 promoter and protects its unmethylated state by its enzymatic activity.

Zampieri M, Passananti C, Calabrese R, Perilli M, Corbi N, De Cave F, Guastafierro T, Bacalini MG, Reale A, Amicosante G, Calabrese L, Zlatanova J, Caiafa P.

PLoS One. 2009;4(3):e4717. doi: 10.1371/journal.pone.0004717. Epub 2009 Mar 5.

7.

Epigenetics: poly(ADP-ribosyl)ation of PARP-1 regulates genomic methylation patterns.

Caiafa P, Guastafierro T, Zampieri M.

FASEB J. 2009 Mar;23(3):672-8. doi: 10.1096/fj.08-123265. Epub 2008 Nov 11. Review.

PMID:
19001527
8.

CCCTC-binding factor activates PARP-1 affecting DNA methylation machinery.

Guastafierro T, Cecchinelli B, Zampieri M, Reale A, Riggio G, Sthandier O, Zupi G, Calabrese L, Caiafa P.

J Biol Chem. 2008 Aug 8;283(32):21873-80. doi: 10.1074/jbc.M801170200. Epub 2008 Jun 5.

9.

Rate of thromboembolic events in mesothelioma.

Nguyen D, Lee SJ, Libby E, Verschraegen C.

Ann Thorac Surg. 2008 Mar;85(3):1032-8. doi: 10.1016/j.athoracsur.2007.11.064.

PMID:
18291192
10.

Advances in the systemic therapy of malignant pleural mesothelioma.

Fennell DA, Gaudino G, O'Byrne KJ, Mutti L, van Meerbeeck J.

Nat Clin Pract Oncol. 2008 Mar;5(3):136-47. doi: 10.1038/ncponc1039. Review.

PMID:
18227828
11.

Chromatin modifications and their function.

Kouzarides T.

Cell. 2007 Feb 23;128(4):693-705. Review.

12.
13.

Survey of differentially methylated promoters in prostate cancer cell lines.

Wang Y, Yu Q, Cho AH, Rondeau G, Welsh J, Adamson E, Mercola D, McClelland M.

Neoplasia. 2005 Aug;7(8):748-60.

14.

Malignant mesothelioma.

Robinson BW, Musk AW, Lake RA.

Lancet. 2005 Jul 30-Aug 5;366(9483):397-408. Review.

PMID:
16054941
15.
16.

Silencing of the thrombomodulin gene in human malignant melanoma.

Furuta J, Kaneda A, Umebayashi Y, Otsuka F, Sugimura T, Ushijima T.

Melanoma Res. 2005 Feb;15(1):15-20.

PMID:
15714116
17.

Modulation of DNMT1 activity by ADP-ribose polymers.

Reale A, Matteis GD, Galleazzi G, Zampieri M, Caiafa P.

Oncogene. 2005 Jan 6;24(1):13-9.

PMID:
15637587
18.
19.

Thrombomodulin.

Weiler H, Isermann BH.

J Thromb Haemost. 2003 Jul;1(7):1515-24. Review.

20.

Venous thromboembolism and cancer: risks and outcomes.

Lee AY, Levine MN.

Circulation. 2003 Jun 17;107(23 Suppl 1):I17-21. Review.

Supplemental Content

Support Center